日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

在富含高危疾病的初治慢性淋巴细胞白血病患者人群中开展的阿卡替尼、维奈克拉和奥妥珠单抗的II期研究

Davids, Matthew S; Ryan, Christine E; Lampson, Benjamin L; Ren, Yue; Tyekucheva, Svitlana; Fernandes, Stacey M; Crombie, Jennifer L; Kim, Austin I; Weinstock, Matthew; Montegaard, Josie; Walker, Heather A; Greenman, Claire; Patterson, Victoria; Jacobson, Caron A; LaCasce, Ann S; Armand, Philippe; Fisher, David C; Lo, Steve; Olszewski, Adam J; Arnason, Jon E; Ahn, Inhye E; Brown, Jennifer R

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

利索卡巴他根马拉鲁塞与二线复发/难治性大B细胞淋巴瘤标准治疗方案对比:来自随机III期TRANSFORM研究的3年随访结果

Kamdar, Manali; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Chow, Victor A; Montheard, Sandrine; Santamaria, Josu; Colicino, Silvia; Ogasawara, Ken; Stepan, Lara; Liu, Fei Fei; Abramson, Jeremy S

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

奥德罗内西他单药治疗CAR-T细胞疗法进展后的复发/难治性弥漫性大B细胞淋巴瘤:ELM-1研究的主要分析

Topp, Max S; Matasar, Matthew; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; Arnason, Jon E; Michot, Jean-Marie; Goldschmidt, Neta; O'Brien, Susan M; Abadi, Uri; Avivi, Irit; Cheng, Yuan; Flink, Dina M; Zhu, Min; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Crombie, Jennifer L

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia

伊布替尼联合乌布拉利西治疗复发/难治性慢性淋巴细胞白血病的1/1b期研究的长期结果

Ryan, Christine E; Ren, Yue; Tyekucheva, Svitlana; Arnason, Jon E; Boruchov, Adam M; Jacobson, Caron A; Fisher, David C; Miskin, Hari; Sportelli, Peter; Brown, Jennifer R; Davids, Matthew S

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

双重难治性和双重暴露慢性淋巴细胞白血病患者的特征和预后

Yoon, James T; Zhou, Yinglu; Mikhaleva, Mariia; Choi, Daniel S; Fernandes, Stacey M; Armand, Philippe; Bessnow, Amy C; Crombie, Jennifer L; Fisher, David C; Jacobsen, Eric D; Jacobson, Caron A; Kim, Austin I; LaCasce, Ann S; Merryman, Reid W; Odejide, Oreofe O; Parry, Erin M; Qualls, David A; Ryan, Christine E; Sekar, Aswin; Soumerai, Jacob D; Arnason, Jon; Tyekucheva, Svitlana; Davids, Matthew S; Brown, Jennifer R; Ahn, Inhye E

Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL

循环肿瘤DNA的早期清除与复发/难治性滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤患者对奥德龙单抗的反应相关

Arnason, Jon E; Matasar, Matthew; Luminari, Stefano; Tucker, David; Sun, Dylan; Tao, Weiwei; Zhu, Yuan O; Kundu, Kunal; Gupta, Namita T; Leary, Allen; Jankovic, Vladimir; Ambati, Srikanth; Mohamed, Hesham; Chaudhry, Aafia; Brouwer-Visser, Jurriaan

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

利索卡巴他根马拉鲁塞治疗复发/难治性套细胞淋巴瘤:来自 TRANSCEND NHL 001(一项 I 期多中心无缝设计研究)套细胞淋巴瘤队列的主要分析

Wang, Michael; Siddiqi, Tanya; Gordon, Leo I; Kamdar, Manali; Lunning, Matthew; Hirayama, Alexandre V; Abramson, Jeremy S; Arnason, Jon; Ghosh, Nilanjan; Mehta, Amitkumar; Andreadis, Charalambos; Solomon, Scott R; Kostic, Ana; Dehner, Christine; Espinola, Ricardo; Peng, Lily; Ogasawara, Ken; Chattin, Amy; Eliason, Laurie; Palomba, M Lia

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

一项评估伊布替尼联合氟达拉滨、环磷酰胺和利妥昔单抗作为慢性淋巴细胞白血病一线治疗方案的II期研究的五年随访结果

Ahn, Inhye E; Brander, Danielle M; Ren, Yue; Zhou, Yinglu; Tyekucheva, Svitlana; Walker, Heather A; Black, Robert; Montegaard, Josie; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A; Armand, Philippe; Ng, Samuel Y; Crombie, Jennifer; Fisher, David C; LaCasce, Ann S; Arnason, Jon; Hochberg, Ephraim P; Takvorian, Ronald W; Abramson, Jeremy S; Brown, Jennifer R; Davids, Matthew S

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

TRANSFORM 研究主要分析结果的简明语言摘要:liso-cell 作为一线治疗方案失败后大 B 细胞淋巴瘤的二线治疗方案

Abramson, Jeremy S; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Ogasawara, Ken; Kamdar, Manali

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Lisocabtagene maraleucel 作为大 B 细胞淋巴瘤二线疗法:3 期 TRANSFORM 研究的主要分析

Abramson, Jeremy S; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Ogasawara, Ken; Kamdar, Manali